Rome Therapeutics was founded to develop novel therapies for cancer and autoimmune diseases by leveraging new insights from the vast uncharted territory of the repeatome.
The repeatome makes up 60% of our genome and consists of repetitive sequences of nucleic acids, known as repeats. These repeats have long been dismissed as “junk DNA.” Much of this region is thought to derive from viruses that embedded in our DNA millions of years ago. In healthy cells, DNA of the repeatome is tightly packed and silent. But when cells are stressed or sick, during circumstances like an infection, cancer or autoimmune disease, this repetitive DNA can unfold, causing the cell to transcribe it into RNA.
Rome believes that medicines targeting the repeatome could revolutionize the way many diseases are treated. The company has already picked out several targets to pursue in cancer and autoimmune disease and is working towards generating small molecule modulators of these targets. Multiple other discovery programs are underway.
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for …
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond …
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an …